Search Patents
  • MK2 inhibitors
    Patent number: 8772286
    Abstract: The present invention relates to compounds of general Formula (I) or a pharmaceutically acceptable salt thereof. The compounds can be used in the treatment of immune, autoimmune, inflammatory diseases, cardiovascular diseases, infectious diseases, bone resorption disorders, neurodegenerative diseases or proliferative diseases.
    Type: Grant
    Filed: December 13, 2010
    Date of Patent: July 8, 2014
    Assignee: Merck Sharp & Dohme B.V.
    Inventors: Tjeerd Andries Barf, Arthur Oubrie, Carsten Schultz-Fademrecht, Eduard Willem Zwart, Niels Hoogenboom, Sander Martijn De Wilde, Allard Kaptein
  • Use of sigma receptor antagonists for treatment of amphetamine abuse
    Patent number: 5162341
    Abstract: The invention relates to a method of treating drug abuse or addiction involving amphetamine or amphetamine-related drugs with pharmacological effects similar to amphetamine in a mammal which comprises administering to the mammal an effective amount, to reduce the pharmacological effects of the amphetamine or amphetamine-related drug, of certain piperidine sigma receptor antagonists.
    Type: Grant
    Filed: February 22, 1991
    Date of Patent: November 10, 1992
    Assignee: Du Pont Merck Pharmaceutical Company
    Inventor: Leonard Cook
  • INHIBITORS OF AKT ACTIVITY
    Publication number: 20110160183
    Abstract: The instant invention provides for substituted naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity by administering the compound to a patient in need of treatment of cancer.
    Type: Application
    Filed: March 11, 2011
    Publication date: June 30, 2011
    Applicant: Merck & Co., Inc.
    Inventors: Michael J. Kelly, III, Mark E. Layton, Philip E. Sanderson
  • 6-amino-pyrimidine-4-carboxamide derivatives and related compounds which bind to the sphingosine 1-phosphate (S1P) receptor for the treatment of multiple sclerosis
    Patent number: 8399448
    Abstract: The invention relates to compounds of formula (I): wherein X, W, Q, R, R1 and R2 have the meanings given in claim 1. The compounds are useful, for example, in the treatment of autoimmune disorders, such as multiple sclerosis.
    Type: Grant
    Filed: July 29, 2008
    Date of Patent: March 19, 2013
    Assignee: Merck Serono SA
    Inventors: Agnes Bombrun, Matthias Schwarz, Stefano Crosignani, David Covini, Delphine Marin
  • Treatment of psychosis using 1-cycloalkylpiperidines
    Patent number: 5296479
    Abstract: There are provided cycloalkyl piperidine compounds which are useful in the treatment of physiological or drug-induced psychosis or dyskinesia in a mammal. These novel compounds are selective sigma receptor antagonists and have a low potential for movement disorder side effects associated with typical antipsychotic agents.
    Type: Grant
    Filed: February 6, 1992
    Date of Patent: March 22, 1994
    Assignee: The Du Pont Merck Pharmaceutical Company
    Inventors: Gary A. Cain, Paul J. Gilligan, Sang W. Tam
  • N-biphenyl(substituted methyl) aminocycloalkane-carboxamide derivatives
    Patent number: 6919343
    Abstract: N-Biphenyl(substituted methyl)aminocycloalkanecarboxamide derivatives are bradykinin B1 antagonists or inverse agonists useful in the treatment or prevention of symptoms such as pain and inflammation associated with the bradykinin B1 pathway.
    Type: Grant
    Filed: January 30, 2003
    Date of Patent: July 19, 2005
    Assignee: Merck & Co., Inc.
    Inventors: Michael R. Wood, Neville J. Anthony, Mark G. Bock, Dong-Mei Feng, Scott D. Kuduk, Dai-Shi Su, Jenny Miu-chun Wai
  • Imidazole, triazole and tetrazole derivatives
    Patent number: 5451588
    Abstract: A class of substituted imidazole, triazole and tetrazole derivatives are selective agonists of 5-HT.sub.1 -like receptors and are therefore useful in the treatment of clinical conditions, in particular migraine and associated disorders, for which a selective agonist of these receptors is indicated.
    Type: Grant
    Filed: November 22, 1993
    Date of Patent: September 19, 1995
    Assignee: Merck Sharp & Dohme Ltd.
    Inventors: Raymond Baker, Victor G. Matassa, Leslie J. Street
  • 6-Amino-Pyrimidine-4-Carboxamide Derivatives and Related Compounds Which Bind to the Sphingosine 1-Phosphate (S1P) Receptor for the Treatment of Multiple Sclerosis
    Publication number: 20100210619
    Abstract: The invention relates to compounds of formula (I): wherein X, W, Q, R, R1 and R2 have the meanings given in claim 15. The compounds are useful e.g. in the treatment of autoimmune disorders, such as multiple sclerosis.
    Type: Application
    Filed: July 29, 2008
    Publication date: August 19, 2010
    Applicant: MERCK SERONO SA
    Inventors: Agnes Bombrun, Matthias Schwarz, Stefano Crosignani, David Covini, Delphine Marin
  • Treatment for cardiovascular disease
    Patent number: 7799794
    Abstract: This invention relates to a method for treating and preventing hypertension by administering a therapeutically effective amount of an agent capable of reducing uric acid levels in a patient in need of such treatment. Additionally, the scope of the invention includes a method of treating coronary heart disease by administering a therapeutically effective amount of an agent capable of reducing uric acid levels in a patient in need of such treatment.
    Type: Grant
    Filed: June 28, 2001
    Date of Patent: September 21, 2010
    Assignees: Merck Sharp & Dohme Corp., University of Washington
    Inventors: Salah Kivlighn, Richard Johnson, Marilda Mazzali
  • HETARYLAMINONAPHTHYRIDINES
    Publication number: 20120316166
    Abstract: Novel hetarylaminonaphthyridine derivatives of formula (I) wherein X, R1, R2, R3, R4, W1, W2, W3, W5 and W6 have the meaning according to claim 1, are inhibitors of ATP consuming proteins, and can be employed, inter alia, for the treatment of tumors.
    Type: Application
    Filed: January 10, 2011
    Publication date: December 13, 2012
    Applicant: MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG
    Inventors: Alfred Jonczyk, Dieter Dorsch, Frank Zenke, Christiane Amendt
  • Use of 5-(7-methoxy-3,3-dimethyl-2,3-dihydro-1-benzoxepin-5-yl)-3-methyl-penta-2,4-dienoic acid as a cosmetic
    Publication number: 20140017187
    Abstract: The invention relates to 5-(7-methoxy-3,3-dimethyl-2,3-dihydro-1-benzoxepin-5-yl)-3-methyl-penta-2,4-dienoic acid and its use in compositions, especially topical, cosmetic and/or personal care compositions, and compositions containing said compound.
    Type: Application
    Filed: July 1, 2013
    Publication date: January 16, 2014
    Applicant: Merck Patent GmbH
    Inventors: Soheila ANZALI, Francis Contard, Jean Jacques Zeiller
  • HETEROARYLAMINOQUINOLINES AS TGF-BETA RECEPTOR KINASE INHIBITORS
    Publication number: 20120225875
    Abstract: Novel hetarylaminoquinoline derivatives of formula (I) wherein X, Z, Het, R1, R2, R3 and R4 have the meaning according to claim 1, are inhibitors of ATP consuming proteins, and can be employed, inter alia, for the treatment of tumors.
    Type: Application
    Filed: October 12, 2010
    Publication date: September 6, 2012
    Applicant: MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG
    Inventors: Alfred Jonczyk, Christiane Amendt, Frank Zenke
  • Tyrosine kinase inhibitors
    Patent number: 6958340
    Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Grant
    Filed: July 26, 2002
    Date of Patent: October 25, 2005
    Assignee: Merck & Co., Inc.
    Inventors: Mark T. Bilodeau, Peter J. Manley, Adrienne Balitza, George D. Hartman, Leonard Rodman
  • Dibenzoazulene derivatives for treating thrombosis, osteoporosis, arteriosclerosis
    Patent number: 6521646
    Abstract: Compounds of the formula (I) and their physiologically acceptable salts and solvates are useful as integrin-inhibiting substances. They are especially useful in the prophylaxis and treatment of cardiovascular disorders, of thrombosis, cardiac infarction, coronary heart diseases, arteriosclerosis, osteoporosis, in pathological conditions that are caused or propagated by angiogenesis and in tumor therapy.
    Type: Grant
    Filed: October 15, 2001
    Date of Patent: February 18, 2003
    Assignee: Merck Patent GmbH
    Inventors: Wolfgang Stähle, Rudolf Gottschlich, Simon Goodman
  • Substituted 1H-pyridinyl-2-ones as GABAA-&agr; 2/3 ligands
    Patent number: 6200982
    Abstract: Substituted 1H-Pyridinyl-2-ones are useful as GABAA-Alpha 2/3 ligands.
    Type: Grant
    Filed: February 11, 2000
    Date of Patent: March 13, 2001
    Assignee: Merck & Dohme Limited
    Inventors: Ian James Collins, Stephen Robert Fletcher, Timothy Harrison, Paul David Leeson, Christopher Richard Moyes, Alan John Nadin, Michael Rowley, Timothy Jason Sparey, Martin Richard Teall
  • Use of 5-(7-methoxy-3,3-dimethyl-2,3-dihydro-1-benzoxepin-5-yl)-3-methyl-penta-2,4-dienoic acid as a cosmetic
    Publication number: 20110144130
    Abstract: The invention relates to 5-(7-methoxy-3,3-dimethyl-2,3-dihydro-1-benzoxepin-5-yl)-3-methyl-penta-2,4-dienoic acid and its use in compositions, especially topical, cosmetic and/or personal care compositions, and compositions containing said compound.
    Type: Application
    Filed: July 27, 2009
    Publication date: June 16, 2011
    Applicant: MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG
    Inventors: Soheila Anzali, Francis Contard, Jean Jacques Zeiller
  • Tetralin compounds
    Patent number: 5132307
    Abstract: New tetralin derivatives of the formula I ##STR1## wherein R.sup.1 to R.sup.8 and Z have the meanings indicated herein and salts thereof, exhibit an effect on the cardiovascular system.
    Type: Grant
    Filed: November 7, 1989
    Date of Patent: July 21, 1992
    Assignee: Merck Patent Gesellschaft mit beschrankter Haftung
    Inventors: Manfred Baumgarth, Rolf Gericke, Rolf Bergmann, Jacques De Peyer, Ingeborg Lues
  • 4,4'-[9H-fluoren-9-ylidenebis (methylene)]bispyrimidine for treating neurological disorders
    Patent number: 5087628
    Abstract: A fluorene compound, 4,4'-[9H-fluoren-9-ylidenebis(methylene)]bispyrimidine, or a pharmaceutically acceptable salt thereof is useful in treating various neurological disorders in mammals. This compound has efficacy over a broad dosage range as measured by hypoxia induced cognition impairment and has a wide safety margin as measured by the ratio of cognition to the onset of overt symptoms.
    Type: Grant
    Filed: January 12, 1990
    Date of Patent: February 11, 1992
    Assignee: Du Pont Merck Pharmaceutical Company
    Inventors: Richard A. Earl, Victor J. DeNoble
  • AMINOPYRIDINE DERIVATIVES FOR TREATING TUMORS AND INFLAMMATORY DISEASES
    Publication number: 20120115861
    Abstract: Compounds of the formula (I), in which R1, R2, R3, R4, R7 and Y have the meanings indicated in Claim 1, are inhibitors of PDK1 and cell proliferation/cell vitality and can be employed for the treatment of tumours and for the treatment of inflammatory diseases.
    Type: Application
    Filed: June 17, 2010
    Publication date: May 10, 2012
    Applicant: MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG
    Inventors: Michel Calderini, Margarita Wucherer-Plietker, Ulrich Graedler, Christina Esdar
  • Iminopyrimidine NMDA NR2B receptor antagonists
    Patent number: 6440976
    Abstract: Compounds described by the chemical structural formula or a pharmaceutically acceptable salt thereof, are useful in the treatment of pain, migraine, depression, anxiety, schizophrenia, Parkinson's disease, stroke, and in the treatment of neuropathies including postherpetic neuralgia, central pain from spinal cord injury, and phantom limb pain.
    Type: Grant
    Filed: June 25, 2001
    Date of Patent: August 27, 2002
    Assignee: Merck & Co., Inc.
    Inventors: David A. Claremon, John A. McCauley, Nigel J. Liverton, Cory R. Theberge